Rallybio Looks To Deals To Grow ‘Transformative’ Rare Disease Pipeline

Rallybio Corp.’s story began when in 2018 a trio of former Alexion Pharmaceuticals Inc. executives, Martin Mackay, Stephen Uden and Jeff Fryer, decided to create their own firm after having collaborated on rare disease drug development since 2013.

“We were motivated by the notion of transformative treatments for patients with rare or ultra-rare diseases,” CEO Mackay told Scrip. Indeed, the name Rallybio was inspired by the idea of people with industry expertise rallying together behind a similar cause, added chief operating officer Uden. The New Haven, CT-based firm went public through a $92.7m offering last summer and has grown from around ten employees pre-pandemic to nearly forty today